Samuel D Rabkin from South Boston, MA, age 71

Us Patents

Use Of Herpes Vectors For Tumor Therapy
view source
US Patent:

6379674, Apr 30, 2002
Filed:

Apr 22, 1998
Appl. No.:

09/064174
Inventors:

Samuel D. Rabkin - Chevy Chase MD
Masahiro Toda - Yokohama, JP
Robert L. Martuza - Chevy Chase MD
Assignee:

Georgetown University - Washington DC
International Classification:

A61K 4800
US Classification:

4241991, 4353201, 435235, 424 21, 424 932, 514 44
Abstract:

Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator.

Replication-Competent Herpes Simplex Virus Mediates Destruction Of Neoplastic Cells
view source
US Patent:

6699468, Mar 2, 2004
Filed:

Jul 25, 2000
Appl. No.:

09/625509
Inventors:

Robert L. Martuza - Chevy Chase MD
Samuel D. Rabkin - Bethesda MD
Toshihiro Mineta - Bethesda MD
Assignee:

Georgetown University - Washington DC
International Classification:

A01N 6300
US Classification:

424 932, 4243201, 514 44
Abstract:

A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the 34. 5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.

Use Of Soluble Costimulatory Factor For Tumor Immuno-Gene Therapy
view source
US Patent:

7064111, Jun 20, 2006
Filed:

Oct 5, 2000
Appl. No.:

09/679147
Inventors:

Tomoki Todo - Belmont MA, US
Samuel D. Rabkin - Lynn MA, US
Robert L. Martuza - Cambridge MA, US
Assignee:

Georgetown University - Washington DC
International Classification:

A61K 48/00
A61K 39/12
A61K 39/245
C12N 15/00
C12N 5/00
US Classification:

514 44, 4353201, 435325, 435455, 4241991, 4242311, 4241341
Abstract:

A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.

Viral Vectors And Their Use In Therapeutic Methods
view source
US Patent:

7749745, Jul 6, 2010
Filed:

Mar 27, 2002
Appl. No.:

10/107036
Inventors:

Paul Johnson - Vancouver, CA
Robert L. Martuza - Cambridge MA, US
Samuel D. Rabkin - Lynn MA, US
Tomoki Todo - Belmont MA, US
Assignee:

Georgetown University - Washington DC
The General Hospital Corporation - Boston MA
MediGene, Inc. - San Diego CA
International Classification:

C12N 7/00
C12N 7/01
A61K 39/245
US Classification:

4352351, 4353201, 435440, 435455, 4242051, 4242311, 424 932, 424 936
Abstract:

The invention provides viral vectors (e. g. , herpes viral vectors) and methods of using these vectors to treat disease.

Replication-Competent Herpes Simplex Virus Mediates Destruction Of Neoplastic Cells
view source
US Patent:

8273568, Sep 25, 2012
Filed:

Mar 1, 2004
Appl. No.:

10/788410
Inventors:

Robert L. Martuza - Chevy Chase MD, US
Samuel D. Rabkin - Bethesda MD, US
Toshihiro Mineta - Bethesda MD, US
Assignee:

Georgetown University - Washington DC
International Classification:

C12N 15/00
C07H 21/02
C07H 21/04
US Classification:

4353201, 536 231
Abstract:

A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the γ34. 5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.

Oncolytic Herpes Simplex Virus Immunotherapy In The Treatment Of Brain Cancer
view source
US Patent:

8313896, Nov 20, 2012
Filed:

Apr 6, 2009
Appl. No.:

12/384633
Inventors:

Robert L. Martuza - Marblehead MA, US
Samuel Rabkin - Swampscott MA, US
William Curry - Boston MA, US
Christopher Farrell - Brookline MA, US
Cecile Zaupa - Bassoues, FR
Assignee:

The General Hospital Corporation - Boston MA
International Classification:

C12Q 1/70
US Classification:

435 5
Abstract:

Method of stimulating an immune response (e. g. , to treat cancer) include administering to a subject a composition including dendritic cells incubated with (i) oHSV-infected tumor cells or a composition derived therefrom, or (ii) tumor cells plus oHSV, as well as methods of preparing such compositions, are described.

Use Of Herpes Vectors For Tumor Therapy
view source
US Patent:

8361978, Jan 29, 2013
Filed:

Aug 20, 2008
Appl. No.:

12/194872
Inventors:

Samuel D. Rabkin - Chevy Chase MD, US
Masahiro Toda - Yokohama, JP
Robert L. Martuza - Chevy Chase MD, US
Assignee:

Georgetown University - Washington DC
International Classification:

A61K 48/00
A61K 39/245
US Classification:

514 44R, 4241991, 4242311
Abstract:

Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator.

Viral Vectors And Their Use In Therapeutic Methods
view source
US Patent:

8470577, Jun 25, 2013
Filed:

Mar 11, 2010
Appl. No.:

12/721599
Inventors:

Paul Johnson - Vancouver, CA
Robert L. Martuza - Cambridge MA, US
Samuel D. Rabkin - Lynn MA, US
Tomoki Todo - Belmont MA, US
Assignee:

Catherex, Inc. - Dover DE
The General Hospital Corporation - Boston MA
Georgetown University - Washington DC
International Classification:

C12N 7/00
C12N 7/01
A61K 39/245
US Classification:

4352351, 4353201, 435440, 435456, 4242051, 4242311, 424 932, 424 936
Abstract:

The invention provides viral vectors (e. g. , herpes viral vectors) and methods of using these vectors to treat disease.